Imaging as a biomarker in drug discovery for Alzheimer's disease: is MRI a suitable technology?
No Thumbnail Available
Date
2014-12-08
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
This review provides perspectives on the utility of magnetic resonance imaging MRI as a neuroimaging approach in the development of novel treatments for Alzheimer s disease These considerations were generated in a roundtable at a recent Wellcome Trust meeting that included experts from academia and industry It was agreed that MRI either structural or functional could be used as a diagnostic for assessing worsening of disease status for monitoring vascular pathology and for stratifying clinical trial populations It was agreed also that MRI implementation is in its infancy requiring more evidence of association with the disease states test retest data better standardization across multiple clinical sites and application in multimodal approaches which include other imaging technologies such as positron emission tomography electroencephalography and magnetoencephalography